Volume 385, Issue 9980, Pages 1843-1852 (May 2015) Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group  Lieke H J Simkens, MD, Harm van Tinteren, PhD, Anne May, PhD, Albert J ten Tije, MD, Geert-Jan M Creemers, MD, Olaf J L Loosveld, MD, Felix E de Jongh, MD, Frans L G Erdkamp, MD, Zoran Erjavec, MD, Adelheid M E van der Torren, MD, Jolien Tol, MD, Hans J J Braun, MD, Peter Nieboer, MD, Prof Jacobus J M van der Hoeven, MD, Janny G Haasjes, MD, Rob L H Jansen, MD, Jaap Wals, MD, Annemieke Cats, MD, Veerle A Derleyn, MD, Aafke H Honkoop, MD, Linda Mol, MSc, Prof Cornelis J A Punt, MD, Dr Miriam Koopman, MD  The Lancet  Volume 385, Issue 9980, Pages 1843-1852 (May 2015) DOI: 10.1016/S0140-6736(14)62004-3 Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile The Lancet 2015 385, 1843-1852DOI: (10.1016/S0140-6736(14)62004-3) Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure 2 Kaplan-Meier analysis for progression-free and overall survival (A) PFS1. (B) PFS2. (C) Time to second progression on any treatment. (D) Overall survival. PFS2=progression-free survival after reintroduction with CAPOX-B. The Lancet 2015 385, 1843-1852DOI: (10.1016/S0140-6736(14)62004-3) Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure 3 Subgroup analyses for PFS2 (A), and overall survival (B) HRs for subgroups are shown with 99% CI, and HR for overall with 95% CI. The numbers in brackets are the number of patients for whom that baseline characteristic is unknown. The Lancet 2015 385, 1843-1852DOI: (10.1016/S0140-6736(14)62004-3) Copyright © 2015 Elsevier Ltd Terms and Conditions